Bio-Rad Laboratories, Inc. filings document operating results, governance, capital structure, and material events for a Delaware company that develops, manufactures, and markets life science research and clinical diagnostics products.
Form 8-K reports furnish quarterly and annual earnings releases, supplemental earnings materials, Regulation FD presentations, Droplet Digital PCR product-portfolio disclosures, and updates related to the company’s investment in Sartorius AG. Proxy materials cover board elections, executive compensation, shareholder voting matters, governance practices, and Class A and Class B common stock disclosures.
BIO-RAD LABORATORIES, INC. (BIO) reported that director Allison Schwartz had restricted stock units vest and convert into Bio-Rad Class A common stock on September 1, 2026. A total of 117 shares of Class A common stock were acquired upon vesting of restricted stock units granted in 2022 and 2023.
The vesting reflects the conversion of 42 restricted stock units from a 2022 grant and 75 restricted stock units from a 2023 grant, each unit representing a contingent right to one Class A share. Of the vested shares, 43 shares were delivered or withheld to cover the exercise price or tax liability at $380.96 per share. No Rule 10b5-1 trading plan is reported for these transactions.
BIO-RAD LABORATORIES, INC. (symbol: BIO) is the issuer of record for a Form 4 filing submitted to the SEC.
Bio-Rad Laboratories reported Q2 2026 net sales of $651.0 million, essentially flat year over year, with gross margin at 53.1%. Life Science sales declined to $252.0 million while Clinical Diagnostics grew to $399.0 million, leaving consolidated operating income at $72.6 million.
Non-operating items dominated results. A $458.0 million gain from changes in the fair value of equity securities and a loan receivable, largely related to the Sartorius position, lifted Q2 net income to $371.4 million, or $13.85 per diluted share. For the first half, however, a $280.2 million fair-value loss on these assets contributed to a net loss of $155.7 million despite $106.7 million of income from operations.
Liquidity remained strong with $1.62 billion in cash, cash equivalents and short-term investments and no borrowings under a $200.0 million revolving credit facility. The $400 million 3.3% Senior Notes due 2027 are now classified as current, and the company indicates sufficient resources to repay or potentially refinance them. A subsequent restructuring plan announced for July 2026 is expected to incur $80 million to $90 million of pre-tax charges through 2027.
Bio-Rad Laboratories reported second-quarter 2026 results and outlined a restructuring plan. Net sales were $651.0 million, essentially flat versus the prior year. GAAP net income was $371.4 million, or $13.85 per diluted share, with results substantially contributed to by a gain from the change in fair value of its Sartorius AG investment. Non-GAAP net income was $70.2 million, or $2.62 per diluted share, roughly in line with 2025.
Operating cash flow was $98.7 million and free cash flow was $66.7 million; the company repurchased approximately $32 million of shares. Life Science revenue declined while Clinical Diagnostics grew modestly. Bio-Rad initiated a strategy-driven global restructuring including headcount reductions, functional consolidation, and facility closures, and expects total pre-tax charges of approximately $80–$90 million, primarily for one-time termination benefits, with substantial completion expected by the end of fiscal 2027. Management reaffirmed full-year 2026 guidance for non-GAAP currency-neutral revenue between about a 3.0% decline and 0.5% growth and a non-GAAP operating margin of roughly 10.0–12.0%.
Eva Anette Engelhardt, EVP and President, CDG of Bio-Rad Laboratories, had 246 Restricted Stock Units vest and convert into 246 shares of Bio-Rad Class A common stock on July 25, 2026. To satisfy tax obligations, 89 of those shares were withheld at $314.4600 per share. After this vesting event, she continues to hold 492 Restricted Stock Units, which vest over four years at 25% per year on the grant anniversary.
Bio-Rad Laboratories executive Eva Anette Engelhardt, EVP and President of the Clinical Diagnostics Group, reported an open-market sale of Bio-Rad A Common Stock. She sold 550 shares on May 11, 2026 at a price of $246.54 per share. After this transaction, she directly holds 346 shares of Bio-Rad A Common Stock.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to sell 550 shares of Common Stock of BIO. The filing lists two restricted-stock lots: 157 shares dated 07/25/2025 and 393 shares dated 09/06/2025.
The notice identifies the securities as restricted stock and is recorded with a filing date of 05/11/2026.
Bio-Rad Laboratories reported Q1 2026 results showing stable sales but a large accounting loss driven by its equity holdings. Net sales were $592.1 million, up slightly from $585.4 million a year earlier, with gross margin steady at 52.3%.
Operating income improved to $34.1 million from $23.7 million, but a $738.2 million loss from changes in fair value of equity securities and a loan receivable, including a $727.7 million holding loss on its Sartorius investment, led to a net loss of $527.1 million versus prior-year net income of $64.0 million.
Cash from operations was $108.1 million, and Bio-Rad ended the quarter with $507.2 million in cash and cash equivalents plus $1,057.5 million in short-term investments. The company repurchased 176,257 Class A shares for $47.8 million and still has $237.1 million available under its 2023 share repurchase program, while carrying $1.2 billion of Senior Notes due 2027 and 2032.
Bio-Rad Laboratories reported first-quarter 2026 net sales of $592.1 million, up 1.1% year over year, but down 4.2% on a currency-neutral basis as both Life Science and Clinical Diagnostics segments faced softer demand.
The company recorded a large GAAP net loss of $527.1 million, or $(19.55) per diluted share, mainly from a $738.2 million loss on the change in fair value of equity securities, including its Sartorius AG investment. On a non-GAAP basis, net income was $50.9 million, or $1.89 per diluted share, down from $2.54 a year earlier, reflecting lower margins and higher adjustments.
Operating cash flow was $108.1 million and free cash flow $78.1 million, both below the prior year, although management highlighted strong cash generation and share repurchases of about 176 thousand shares. Bio-Rad also lowered its full-year 2026 outlook, now expecting non-GAAP currency-neutral revenue between a 3.0% decline and 0.5% growth and a non-GAAP operating margin of roughly 10.0% to 12.0%, down from its prior 12.0% to 12.5% margin range.